StockTitan

@stocktitan.net

1 week ago

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth Tevogen (Nasdaq: TVGN) is in advanced-stage evaluation to acquire a niche contract research organization operating in 20+ countries, targeting oncology, rare diseases, and medical devices. If completed, the deal is expected to add $20M+ in annual revenue and support double-digit growth beginning next year.The company said the combination would expand global clinical capabilities and help build a scalable, cash-flow-oriented healthcare business; management also cited a potential path toward ~$100M in annual revenue pending additional transactions and execution.

#TVGN #TVGNW Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

www.stocktitan.net/news/TVGN/tevogen-advanc...

StockTitan

@stocktitan.net

3 weeks ago

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization Tevogen (Nasdaq: TVGN) reaffirmed capital discipline on March 13, 2026: the lead investor intends to maintain current holdings and the company does not expect to use more than 1% of authorized shares over the next 12 months or until cash-flow positive.The company said only about 20% of shares are in the tradable float after excluding insider holdings, is prioritizing milestone‑linked stock incentives, is evaluating a one‑time special cash dividend contingent on financial milestones, and is assessing acquisitions that could add $50M+ combined annual revenue; Tevogen noted GAAP may not reflect full asset value and cited independent 2022 valuation above $4B.

#TVGN #TVGNW Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

www.stocktitan.net/news/TVGN/tevogen-reaffi...

StockTitan

@stocktitan.net

3 weeks ago

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI. Tevogen.AI was built to solve a critical challenge in drug

#TVGN #TVGNW Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

www.stocktitan.net/news/TVGN/tevogen-ai-rep...

StockTitan

@stocktitan.net

1 month ago

Letter to Shareholders from CEO Dr. Ryan Saadi Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN). Dear Shareholders, As we continue executing on Tevogen’s long-term strategy to evolve into a sustainable, revenue-generating healthcare enterprise, I would like to provide an update

#TVGN #TVGNW Letter to Shareholders from CEO Dr. Ryan Saadi

www.stocktitan.net/news/TVGN/letter-to-shar...

StockTitan

@stocktitan.net

1 month ago

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical Tevogen (Nasdaq: TVGN) signed a non-exclusive, non-binding Letter of Intent dated March 5, 2026 to evaluate a potential acquisition of Apozeal Pharmaceutical. The deal could provide Tevogen Generics with an established platform including 11 FDA-approved ANDA products, multiple ANDAs pending, and additional generics in development.The transaction is subject to due diligence, negotiation of definitive agreements, regulatory approvals, and customary closing conditions, and there is no assurance the acquisition will be completed.

#TVGN #TVGNW Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

www.stocktitan.net/news/TVGN/tevogen-advanc...

StockTitan

@stocktitan.net

1 month ago

Tevogen Announces Reverse Stock Split Tevogen (Nasdaq: TVGN) announced a 50-for-1 reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid requirement. The split is expected to be effective at 12:01 a.m. on March 6, 2026, with shares trading on a split-adjusted basis under the same symbol and a new CUSIP.No fractional shares will be issued; holders entitled to fractions will receive cash in lieu. Equity awards, warrants, incentive plan shares and preferred conversions will be proportionally adjusted. The company said the split will not affect underlying operations or total stockholders' equity.

#TVGN #TVGNW Tevogen Announces Reverse Stock Split

www.stocktitan.net/news/TVGN/tevogen-announ...

StockTitan

@stocktitan.net

1 month ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization Tevogen (Nasdaq: TVGN) announced a signed, non-exclusive, non-binding Letter of Intent dated Feb 27, 2026 to evaluate a potential acquisition of a global Contract Research Organization (CRO).If completed, the transaction could expand clinical development capabilities, add revenue-generating services, and support a more capital-efficient growth model while remaining subject to due diligence and definitive agreements.

#TVGN #TVGNW Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

www.stocktitan.net/news/TVGN/tevogen-signs-...

StockTitan

@stocktitan.net

1 month ago

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus Tevogen (Nasdaq: TVGN) signed a non-exclusive, non-binding Letter of Intent on Feb 26, 2026 to evaluate a potential transaction to acquire a majority voting interest in Sciometrix and its Clinicus digital care management platform.The deal would aim to make Tevogen a revenue-generating healthcare enterprise by integrating Clinicus' remote patient monitoring and predictive analytics with Tevogen.AI to support commercialization, value-based care, and optimized clinical trials; the transaction is subject to due diligence, definitive documentation, approvals and customary closing conditions.

#TVGN #TVGNW UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

www.stocktitan.net/news/TVGN/update-tevogen...

StockTitan

@stocktitan.net

1 month ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus Tevogen (Nasdaq: TVGN) signed a non-exclusive, non-binding Letter of Intent on Feb. 26, 2026 to evaluate a potential transaction to acquire a majority voting interest in Sciometrix and its Clinicus digital care management platform.The deal, if completed, would aim to make Tevogen a revenue-generating healthcare enterprise by integrating Clinicus and remote patient monitoring with Tevogen.AI to accelerate commercialization readiness and enhance data, analytics, and value-based care capabilities. The proposal remains subject to due diligence, definitive agreements, approvals, and customary closing conditions.

#TVGN #TVGNW Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

www.stocktitan.net/news/TVGN/tevogen-signs-...

StockTitan

@stocktitan.net

3 months ago

CEO gives 230,000 company shares to support underserved communities Tevogen founder Ryan Saadi donates 230,000 shares to SRLC USA, a UN‑recognized 501(c)(3); the Rule 144 transaction gives him no proceeds.

#TVGN #TVGNW Tevogen CEO Donates Shares to Support Education for Underprivileged Children

www.stocktitan.net/news/TVGN/tevogen-ceo-do...

StockTitan

@stocktitan.net

3 months ago

Tevogen CEO Donates Personal Shares to Support Local Fire Department Tevogen (Nasdaq: TVGN) Founder and CEO Dr. Ryan Saadi donated 50,000 shares of his personal Tevogen common stock to the Mt. Bethel Fire Company to support emergency readiness in Warren Township on December 19, 2025. The contributed shares are intended to enhance safety, equipment and response capabilities.The donation was executed under SEC Rule 144, and Dr. Saadi will not receive proceeds from any disposal of the securities. The announcement also states an estimated $10 billion asset valuation for the company and a secured cash runway through commercialization.

#TVGN #TVGNW Tevogen CEO Donates Personal Shares to Support Local Fire Department

www.stocktitan.net/news/TVGN/tevogen-ceo-do...

StockTitan

@stocktitan.net

3 months ago

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock Tevogen (Nasdaq: TVGN) announced that Founder and CEO Dr. Ryan Saadi donated 230,000 personal shares of common stock to the Warren Township Honorary Policemen’s Benevolent Association (P.B.A.) Local 235 on Dec. 11, 2025. The nonprofit supports local schools, D.A.R.E., Explorer programs, families of fallen/injured officers, and community events. The donation will fund equipment to enhance officer and resident safety. The transfer was made in accordance with SEC Rule 144 and Dr. Saadi will not receive proceeds from the disposal of the securities.

#TVGN #TVGNW Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock

www.stocktitan.net/news/TVGN/tevogen-ceo-su...

StockTitan

@stocktitan.net

4 months ago

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook Tevogen (Nasdaq: TVGN) was named to the 2025 New Jersey Power List by NJBIZ for influence on New Jersey's economic and innovation landscape.NJBIZ highlighted Tevogen's ExacTcell platform, advancing pipelines in infectious disease, oncology, and neurology, and its internally developed PredicTcell AI for target prediction. The recognition referenced an anticipated ~$1 billion in first-year specialty-care revenue and a cumulative five-year forecast of $18–22 billion. Tevogen also noted expansion including a 17,428-square-foot manufacturing facility and a new headquarters that more than doubles its prior footprint, centralizing R&D, regulatory, and Tevogen.AI operations.

#TVGN #TVGNW Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

www.stocktitan.net/news/TVGN/tevogen-recogn...

StockTitan

@stocktitan.net

4 months ago

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q Tevogen (Nasdaq: TVGN) filed its Form 10-Q for the quarter ended September 30, 2025, reporting continued capital-efficient execution.Key metrics: GAAP loss from operations of $5.7M for Q3 2025 and $21.5M for the nine months ended Sept 30, 2025; Adjusted loss from operations was $2.5M (Q3) and $7.8M (nine months), representing a 10% and 25% reduction versus the comparable 2024 periods. The company highlights investments in workforce, IT, and Tevogen.AI while emphasizing cost-efficient drug development.

#TVGN #TVGNW Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

www.stocktitan.net/news/TVGN/tevogen-highli...

StockTitan

@stocktitan.net

5 months ago

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID This milestone expands patient eligibility through multi-HLA targeting Builds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patients TVGN 489 utilizes off-the-shelf, genetically unmodified allogeneic T cells TVGN 489 is

#TVGN #TVGNW Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

www.stocktitan.net/news/TVGN/tevogen-report...

StockTitan

@stocktitan.net

5 months ago

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn Tevogen (Nasdaq: TVGN) clarified its reported accumulated deficit and provided cash-versus-noncash context for investors on Nov 3, 2025. The company said it has raised under $42 million in total cash to June 30, 2025, while GAAP shows an accumulated deficit of $129 million. Management explained that backing out cash yields a cash loss of ~ $41 million and about $88 million of non-cash expenses, offset by $110 million in Additional Paid-in Capital and a capital raise of over $8.8 million, leaving a stockholders’ deficit of under $9.5 million.The company plans to publish reconciled non-GAAP metrics with its Form 10-Q for Q3 2025 and reiterated forward-looking risks including the need for additional capital.

#TVGN #TVGNW Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

www.stocktitan.net/news/TVGN/tevogen-clarif...

StockTitan

@stocktitan.net

5 months ago

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore its biopharma model centered on sustainability and patient affordability, highlighting the

#TVGN #TVGNW Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

www.stocktitan.net/news/TVGN/tevogen-senior...

StockTitan

@stocktitan.net

6 months ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion Tevogen (NASDAQ:TVGN) announced significant advancements in its PredicTcell™ AI platform for T cell-based therapies. The beta version has expanded its training dataset to ~1.4 million records and total dataset to over 6.7 billion records, marking a 100-fold increase.The platform, developed with Microsoft and Databricks, builds upon the alpha version which achieved 92-97% recall levels and 38-43% precision. The beta version analyzes over 10.7 billion data points, including 6.5 billion virology, 4.2 billion genomic, and 416 million oncology datapoints, while expanding training features from 22 to 27.This advancement could potentially enable T-cell therapies to bind to their targets with unprecedented accuracy, promising increased clinical success rates, shorter development timelines, and improved patient access to life-saving therapies.

#TVGNW #TVGN Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

www.stocktitan.net/news/TVGNW/tevogen-marks...

StockTitan

@stocktitan.net

6 months ago

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID Tevogen Bio (NASDAQ:TVGN) has highlighted the potential of its investigational T cell therapy TVGN 489 in treating Long COVID, which affects an estimated 20 million Americans. Recent peer-reviewed studies have linked Long COVID to persistent viral reservoirs, where SARS-CoV-2 proteins and RNA remain in the body for months to years after infection.TVGN 489, developed using Tevogen's ExacTcell™ platform, is an off-the-shelf cytotoxic CD8+ T lymphocyte therapy targeting multiple SARS-CoV-2 proteins. In proof-of-concept trials, the therapy demonstrated efficacy in reducing viral load in all patients, with CTLs persisting for at least 6 months without interfering with patients' immune responses.The company is actively preparing for clinical manufacturing of TVGN 489, which could potentially restore homeostasis in Long COVID patients by eliminating virus-infected cells.

#TVGNW #TVGN Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

www.stocktitan.net/news/TVGNW/tevogen-highl...

StockTitan

@stocktitan.net

6 months ago

20 Million Americans With Long COVID Could Benefit from Tevogen's Breakthrough TVGN 489 Treatment Biotech firm Tevogen highlights TVGN 489's potential impact on 20M US Long COVID patients following HHS roundtables. Drug shows promising results in Proof-of-Concept trial.

#TVGNW #TVGN Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

www.stocktitan.net/news/TVGNW/tevogen-comme...

StockTitan

@stocktitan.net

6 months ago

$6.5 Billion Revenue Forecast: Tevogen's Novel Liver Cancer Prevention Drug for Hepatitis B Patients Biotech firm Tevogen estimates $6.5B in 5-year revenue for TVGN 116 targeting liver cancer prevention in Hepatitis B patients. US market rNPV projected at $325M.

#TVGNW #TVGN Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

www.stocktitan.net/news/TVGNW/tevogen-estim...

StockTitan

@stocktitan.net

7 months ago

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform Tevogen (Nasdaq: TVGN) has announced a risk-adjusted net present value (rNPV) of $9-11 billion for TVGN-489, its first clinical-stage allogeneic precision T cell therapy from the ExacTcell™ platform. The therapy targets SARS-CoV-2 infection in high-risk patients and Long-COVID cases.Phase I clinical trial results published in Blood Advances demonstrated significant efficacy: 92% of patients showed ≥88% viral elimination by Day 4, and 100% achieved >99% elimination by Day 14. The treatment showed excellent safety with no major adverse events and maintained effectiveness against viral mutations, including the XFG variant.Notably, two cancer patients successfully underwent stem cell transplants shortly after TVGN-489 treatment without COVID-19 complications, suggesting thorough viral eradication. The valuation reflects US-only revenue potential and excludes the broader ExacTcell™ platform value.

#TVGNW #TVGN Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

www.stocktitan.net/news/TVGNW/tevogen-value...

StockTitan

@stocktitan.net

7 months ago

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas Tevogen (NASDAQ:TVGN) has revealed significant valuation metrics for its pipeline product TVGN 930, targeting EBV-associated leukemia and lymphomas. The company projects a risk-adjusted Net Present Value (rNPV) exceeding $250 million in the US market alone, with an estimated 5-year cumulative revenue forecast of $3.5 billion.The therapeutic candidate addresses an accessible US market of up to 40,000 patients across five rare disease indications. Notably, TVGN 930 aims to fill a significant therapeutic gap, as there are currently no approved EBV vaccines or effective treatments. The company's development approach leverages a unique, faster, and cost-efficient drug development model.

#TVGNW #TVGN Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

www.stocktitan.net/news/TVGNW/tevogen-share...

StockTitan

@stocktitan.net

7 months ago

99% COVID Elimination: Tevogen's Novel T Cell Therapy Shows Promise for Immunocompromised Patients Tevogen's TVGN 489 T cell therapy achieves >99% SARS-CoV-2 elimination by day 14 in high-risk patients. Treatment shows 6-month CTL persistence and efficacy against XFG variant.

#TVGNW #TVGN Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

www.stocktitan.net/news/TVGNW/tevogen-under...

StockTitan

@stocktitan.net

7 months ago

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure Tevogen Bio (NASDAQ:TVGN) announced plans to disclose detailed valuations of its significant internally developed assets, which are currently not reflected on the company's balance sheet under U.S. GAAP rules. The company's key assets include three granted and twelve pending U.S. patents, including two in artificial intelligence.Tevogen highlighted its proprietary ExacTcell™ platform for developing CD8+ cytotoxic T lymphocytes, and AI technologies including PredicTcell™ and AdapTcell™, developed through strategic partnerships with Microsoft and Databricks. The company's clinical pipeline focuses on cancer therapeutics with potential expansion into non-oncology indications.The company maintains drug discovery facilities at CIC Philadelphia, headquarters in New Jersey, and is developing internal GMP manufacturing capabilities. Tevogen reports being well-capitalized with access to a line of credit for current operations.

#TVGNW #TVGN Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

www.stocktitan.net/news/TVGNW/tevogen-bio-h...

StockTitan

@stocktitan.net

7 months ago

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions Tevogen Bio Holdings (Nasdaq: TVGN) reported significant growth in institutional ownership during Q2 2025. The company saw a 24% increase in institutional ownership compared to Q1 2025, following a 60% increase in the previous quarter.Notable developments include Morgan Stanley and BlackRock increasing their combined holdings by 80%. The number of institutional holders grew from 51 to 55, with 72% of holders either increasing or maintaining their positions. The company attributes this growth to its scientific and operational progress, including positive clinical data and advancement toward internal GMP cell manufacturing capabilities.

#TVGNW #TVGN Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

www.stocktitan.net/news/TVGNW/tevogen-sees-...

StockTitan

@stocktitan.net

7 months ago

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts Tevogen Bio (Nasdaq: TVGN) has secured a financing agreement worth up to $50 million, comprising a $36 million line of credit and a potential $14 million private placement. This follows the company's recent elimination of $94.9 million in balance sheet liabilities.The line of credit allows access to $1 million monthly at an interest rate of either daily SOFR plus 2.0% or 7.0%, payable in common stock at $1.50 per share. The private placement option activates when the 10-day volume weighted average share price reaches $10 per share, priced at a 30% discount.The funding will support R&D efforts, particularly for TVGN 489 from their ExacTcell™ platform, and strengthen their IP portfolio of 3 granted US patents, 9 pending US applications, and 12 ex-US applications.

#TVGNW #TVGN REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

www.stocktitan.net/news/TVGNW/repeat-tevoge...

StockTitan

@stocktitan.net

7 months ago

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum Tevogen Bio Holdings (NASDAQ:TVGN) reported improved financial results for Q2 2025, with a significant reduction in operating losses to $5.4 million compared to $8.6 million in Q2 2024. The company's net loss decreased to $5.5 million from $9.7 million in the same period last year.The company is focusing on operational efficiency while building infrastructure, advancing AI capabilities, and establishing its own GMP manufacturing facility. Tevogen maintains access to financing to support its growth plans and anticipates generating revenue by the end of 2026. Management acknowledges concerns about limited tradable float and is actively exploring options to address investor demand.

#TVGNW #TVGN Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

www.stocktitan.net/news/TVGNW/tevogen-deliv...

StockTitan

@stocktitan.net

7 months ago

10,000 Shares Worth Donated: Tevogen Bio CEO Makes Personal Stock Gift to Support Local Law Enforcement Tevogen Bio founder Dr. Ryan Saadi donates 10,000 personal shares to Warren Township PBA Local 235, supporting community programs, D.A.R.E., and assistance for police families.

#TVGNW #TVGN Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

www.stocktitan.net/news/TVGNW/tevogen-ceo-d...

StockTitan

@stocktitan.net

7 months ago

10,000 Shares Donated: Tevogen CEO Supports Brain Injury Recovery Through Opportunity Project Gift Tevogen Bio founder Dr. Ryan Saadi donates 10,000 personal shares to Opportunity Project, a NJ nonprofit serving 600+ brain injury patients since 1993. SEC Rule 144 compliant transfer.

#TVGNW #TVGN Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

www.stocktitan.net/news/TVGNW/tevogen-ceo-d...